| pubmed-article:10190716 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10190716 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10190716 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10190716 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:10190716 | lifeskim:mentions | umls-concept:C0004359 | lld:lifeskim |
| pubmed-article:10190716 | lifeskim:mentions | umls-concept:C0010798 | lld:lifeskim |
| pubmed-article:10190716 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:10190716 | lifeskim:mentions | umls-concept:C0242831 | lld:lifeskim |
| pubmed-article:10190716 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10190716 | pubmed:dateCreated | 1999-6-29 | lld:pubmed |
| pubmed-article:10190716 | pubmed:abstractText | Cytochrome P450 2D6 (CYP2D6) has been documented as the major target antigen of liver kidney microsomal autoantibodies type-1 (anti-LKM-1) in both autoimmune hepatitis type-2 (AIH-2) and hepatitis C (HCV). In HCV/anti-LKM-1-positive patients, the choice between alpha-interferon (alpha-IFN) or immunosuppression may be difficult. This study was conducted to evaluate the course and outcome of alpha-IFN therapy in HCV/anti-LKM-1-positive and -negative patients and the alterations in these autoantibody titers by the indirect immunofluorescence and a novel radioligand assay. Epitope mapping was also performed to screen for a potential shift in anti-LKM-1 binding towards small linear epitopes, which are more often detected in AIH-2 patients. | lld:pubmed |
| pubmed-article:10190716 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10190716 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10190716 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10190716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10190716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10190716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10190716 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10190716 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10190716 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10190716 | pubmed:issn | 0168-8278 | lld:pubmed |
| pubmed-article:10190716 | pubmed:author | pubmed-author:MannoM LML | lld:pubmed |
| pubmed-article:10190716 | pubmed:author | pubmed-author:FrankHH | lld:pubmed |
| pubmed-article:10190716 | pubmed:author | pubmed-author:BarusBB | lld:pubmed |
| pubmed-article:10190716 | pubmed:author | pubmed-author:KayserAA | lld:pubmed |
| pubmed-article:10190716 | pubmed:author | pubmed-author:DalekosG NGN | lld:pubmed |
| pubmed-article:10190716 | pubmed:author | pubmed-author:Obermayer-Str... | lld:pubmed |
| pubmed-article:10190716 | pubmed:author | pubmed-author:WedemeyerHH | lld:pubmed |
| pubmed-article:10190716 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10190716 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:10190716 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10190716 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10190716 | pubmed:pagination | 366-75 | lld:pubmed |
| pubmed-article:10190716 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:meshHeading | pubmed-meshheading:10190716... | lld:pubmed |
| pubmed-article:10190716 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10190716 | pubmed:articleTitle | Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. | lld:pubmed |
| pubmed-article:10190716 | pubmed:affiliation | Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Germany. | lld:pubmed |
| pubmed-article:10190716 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10190716 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10190716 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10190716 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10190716 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10190716 | lld:pubmed |
